Abstract
Transforming growth factor (TGF)-β signaling is a potent modulator of the invasive and metastatic behavior of breast cancer cells. Indeed, breast tumor responsiveness to TGF-β is important for the development of osteolytic bone metastases. However, the specific TGF-β isoforms that promote breast cancer outgrowth in bone is unknown. We demonstrate that expression of a TGF-β ligand trap, which neutralizes TGF-β1 and TGF-β3, in MDA-MB-231 breast cancer cells diminished their outgrowth in bone and reduced the severity of osteolytic lesion formation when compared with controls. We further show that a reduction or loss of TGF-β1 expression within the bone microenvironment of TGF-β1+/− and TGF-β1−/− mice significantly reduced the incidence of breast tumor outgrowth compared with wild-type animals. Interestingly, those tumors capable of growing within the tibiae of TGF-β1-deficient mice had upregulated expression of all three TGF-β isoforms. Finally, breast cancer cells expressing the TGF-β ligand trap showed a pronounced reduction in their ability to form osteolytic lesions when injected into the tibiae of TGF-β1+/− mice. Thus, our studies show that both host- and tumor-derived TGF-β expression plays a critical role during the establishment and outgrowth of breast cancer cells in bone.
Similar content being viewed by others
Abbreviations
- CM:
-
conditioned media
- ECD:
-
extracellular domain
- IL-11:
-
interleukin-11
- PTHrP:
-
parathyroid hormone-related protein
- TβRI:
-
TGF-β type I receptor
- TβRII:
-
TGF-β type II receptor
- TGF-β:
-
transforming growth factor β
- VC:
-
vector control
References
Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM et al. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714–6721.
Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A et al. (2008). TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13: 217–236.
Broussau S, Jabbour N, Lachapelle G, Durocher Y, Tom R, Transfiguracion J et al. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16: 500–507.
Coleman RE . (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s–6249s.
De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y et al. (2006). Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J Mol Biol 355: 47–62.
Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G et al. (2006). The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202–2209.
del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY . (2004). In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem 279: 22765–22772.
Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K et al. (2007). Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98: 127–133.
Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T . (1999). Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59: 3379–3386.
Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH . (1998). Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 23: 87–93.
Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB et al. (2008). Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29: 157–168.
Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer A et al. (2001a). TGFbeta1 and TGFbeta2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 109: 217–226.
Hering S, Isken F, Janott J, Jost C, Pommer A, Muhr G et al. (2001b). Analysis of TGFbeta3 gene expression and protein levels in human bone and serum. Exp Clin Endocrinol Diabetes 109: 107–115.
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R et al. (2006). Metastatic patterns in adenocarcinoma. Cancer 106: 1624–1633.
Janssens K, ten Dijke P, Janssens S, Van Hul W . (2005). Transforming growth factor-beta1 to the bone. Endocr Rev 26: 743–774.
Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA et al. (2002). Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277: 24571–24578.
Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909–13914.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537–549.
Komesli S, Vivien D, Dutartre P . (1998). Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 254: 505–513.
Kozlow W, Guise TA . (2005). Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10: 169–180.
Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC et al. (1993). Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770–774.
Liao J, McCauley LK . (2006). Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25: 559–571.
Lopez-Casillas F, Wrana JL, Massague J . (1993). Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73: 1435–1444.
Manolagas SC . (1995). Role of cytokines in bone resorption. Bone 17: 63S–67S.
Mastro AM, Gay CV, Welch DR . (2003). The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 20: 275–284.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M et al. (2005). Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44–55.
Mourskaia AA, Northey JJ, Siegel PM . (2007). Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med Chem 7: 504–514.
Moustakas A, Heldin CH . (2005). Non-Smad TGF-beta signals. J Cell Sci 118: 3573–3584.
Mundy GR . (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.
Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ et al. (2008). Signaling through ShcA is required for TGF-{beta} and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol Cell Biol 28: 3162–3176.
Pfaffl MW . (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
Rose AA, Siegel PM . (2006). Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 93: 931–943.
Schmierer B, Hill CS . (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970–982.
Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. (1992). Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693–699.
Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ . (2001). Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 169: 87–95.
Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR et al. (1998). Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4: 802–807.
Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA . (1991). Expression cloning and characterization of the TGF-beta type III receptor. Cell 67: 797–805.
Wrana JL, Attisano L, Wieser R, Ventura F, Massague J . (1994). Mechanism of activation of the TGF-beta receptor. Nature 370: 341–347.
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R et al. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197–206.
Yoneda T, Hiraga T . (2005). Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679–687.
Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R . (2001). A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486–1495.
Acknowledgements
We thank Dr Joan Massagué for providing the MDA-MB-231 derivative cell populations used in this study. We are grateful to Caterina Russo for providing excellent technical support, and acknowledge the McGill Centre for Bone and Periodontal Research for routine histological services. We thank Dr Ursini-Siegel, Dr Le Nihouannen and members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. This study was supported by grants from the Canadian Breast Cancer Research Alliance (nos. 015333 and MOP-84386). AA Mourskaia is supported by a studentship from Fonds de la Recherche en Santé du Québec and PM Siegel is a research scientist of the National Cancer Institute of Canada.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Mourskaia, A., Dong, Z., Ng, S. et al. Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 28, 1005–1015 (2009). https://doi.org/10.1038/onc.2008.454
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.454
- Springer Nature Limited
Keywords
This article is cited by
-
Limb-bud and Heart (LBH) Functions as a Tumor Suppressor of Nasopharyngeal Carcinoma by Inducing G1/S Cell Cycle Arrest
Scientific Reports (2015)
-
Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
Clinical and Translational Oncology (2015)
-
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis
Breast Cancer Research (2012)
-
ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone
Breast Cancer Research (2012)
-
Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes
Oncogene (2011)